- $430.64m
- $867.92m
- $457.43m
- 54
- 68
- 66
- 66
2019 December 31st | 2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,056 | 912 | 472 | 463 | 457 |
Cost of Revenue | |||||
Gross Profit | 722 | 600 | 296 | 294 | 290 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,083 | 1,135 | 450 | 510 | 488 |
Operating Profit | -27.8 | -223 | 21.8 | -46.5 | -30.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -27.7 | -221 | 20.6 | -54.5 | -50.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -27.9 | -179 | 16.4 | -46.9 | -56 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -28 | -179 | -95.3 | -63.9 | -393 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -28 | -179 | -95.3 | -63.9 | -393 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.948 | -3.03 | 0.977 | -1.07 | -1.64 |